Automakers push back against India's proposed emission norms
Corporate Average Fuel Efficiency
(CAFE) norms.
A high-level meeting is scheduled for July 2 in New Delhi, where automakers are expected to present their concerns directly to Transport Minister Nitin Gadkari.
SIAM proposal to Ministry of Power
In a formal submission to the Ministry of Power, the
Society of Indian Automobile Manufacturers
(SIAM) warned that the accelerated reduction targets could result in billions of rupees in penalties and deter future investments in the country's ₹11.4 lakh crore auto industry. The current proposal suggests emission cuts at twice the pace of the previous target.
The draft plan also recommends applying different fuel-efficiency standards for smaller, lighter vehicles versus heavier ones — a move seen as favouring manufacturers like Maruti Suzuki and Toyota Kirloskar, who are investing in CNG and hybrid technologies. However, SIAM argues that splitting standards by vehicle weight could compromise policy cohesion and skew market competition.
What are the demands?
Automakers are also urging the government to extend emissions credits to hybrid, ethanol-blended, and gas-powered vehicles — benefits currently reserved for electric vehicles. Additionally, the government is considering ending petrol and diesel car sales by 2040, a proposal that has seen continued resistance.
The industry is instead proposing a more gradual 15 per cent reduction target, along with emission credit adjustments for E20 fuel and biogas vehicles, and the creation of a carbon trading system to allow credit exchange among automakers.
The final policy direction could define India's clean mobility landscape for years, as the government navigates the delicate balance between climate goals and economic realities for a country of 1.4 billion people.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
39 minutes ago
- Mint
Airbus Said to Deliver Fewer Aircraft in July Amid Engine Woes
(Bloomberg) -- Airbus SE delivered about 63 aircraft last month, roughly 18% fewer than during the same month a year ago, as a shortage of engines on its best-selling A320neo model hampered handovers to customers, people familiar with the matter said. The world's biggest planemaker has delivered around 370 planes in the first seven months of 2025, less than half its annual goal. July delivery figures are preliminary and could change slightly, the people cautioned, asking not to be identified discussing confidential data. An Airbus spokesperson declined to comment on the July tally ahead of official publication of figures next week. Deliveries are closely watched by investors because that is when airline customers pay over the bulk of the money for an aircraft order. This week, Airbus's Chief Executive Officer Guillaume Faury said that while the company continued to maintain its full year guidance of around 820 handovers, supply chain issues would push out the bulk of the deliveries into the second half of the year. By comparison, Airbus delivered 77 jets in July a year ago, taking seven month handovers to 400 at that point. The company had 60 so-called gliders — newly built aircraft on the ground without engines — at the end of June, a number it aims to eradicate by the end of the year, Airbus management said on an earnings call on Wednesday. Boeing Co. has been ramping up production of its competing 737 Max jet and has been catching up to its European rival. It was neck-and-neck with Airbus at the half year mark with 280 deliveries versus 306 at the European planemaker. The US planemaker has been working to return its factories to a steadier tempo. It's also cushioned by a surplus of inventory as a consequence of a strike in late 2024 and its decision earlier in the year to slow production to address quality shortfalls after a door-shaped panel blew out of an airborne 737 Max. More stories like this are available on
Time of India
3 hours ago
- Time of India
Apple CEO Tim Cook on Apple's 18 Years journey to 3 Billion iPhones
Apple has now shipped three billion iPhones since the launch of the original iPhone 18 years ago, in 2007. During Apple's third-quarter earnings call, CEO Tim Cook revealed that the company shipped its three billionth iPhone during the quarter. Apple also reported $94 billion in revenue, with iPhone sales contributing $44.6 billion, nearly half of its total quarterly revenue. While it took nine years to reach the first billion iPhones sold in 2016, the company hit two billion by 2021, just five years later. The jump from two to three billion took only four years, signaling growing global demand despite market saturation concerns. iPhone sales jumped 13% year-over-year in the quarter ending June 2025, with analysts suggesting tariff concerns may have driven purchases. Bloomberg reporter Mark Gurman noted that consumers likely bought iPhones fearing future price increases due to President Trump's proposed tariffs, which already cost Apple $800 million last quarter and are projected to reach $1.1 billion next quarter. While company executive Eddy Cue recently admitted consumers "may not need an iPhone 10 years from now," CEO Tim Cook pushed back against concerns about advanced AI replacing the iPhone, stating "it's difficult to see a world" without iPhones during Q3 2025 earnings call. Apple's slow rollout of AI features has left analysts mixed on its competitive edge, even as the company attempts to diversify through its Vision Pro headset and expanded AI initiatives.
Mint
5 hours ago
- Mint
Novo Nordisk Shares Post Worst Ever Week as Optimism Wanes
(Bloomberg) -- Just six weeks ago, things seemed to be getting better for Novo Nordisk A/S. Investors were optimistic, and the Danish drugmaker was briefly Europe's most valuable public company again. Now, the stock has posted its worst week on record. The shares have plunged 32% this week after the maker of Ozempic and Wegovy cut its forecasts for the year and named a company insider as its new chief executive officer. The stock was also hit on Friday after US President Donald Trump demanded that pharmaceutical companies lower American drug prices. That's taken Novo's market capitalization to the equivalent of $213 billion — below companies including Nestle SA and AstraZeneca Plc. The Danish firm dropped out of Europe's top 10 most valuable stocks on Friday morning, before regaining the final slot in that list later in the day. 'We've long been calling Novo a 'show me' story,' Barclays Plc analyst Emily Field wrote in a note this week. But with Novo having a hard time competing with cheaper, copycat versions of its medicines, and a new drug pipeline that lags behind rivals, 'we struggle to see what will get investors to return' to the story, Field wrote, downgrading the stock to equal-weight from overweight. Novo's warning on Tuesday followed a tumultuous year that's seen the shares plunge 70% from last summer's record high. Issues have included disappointing clinical trial results for experimental drugs, mounting competition from Eli Lilly & Co. and the ouster of its former CEO. Novo named company veteran Maziar Mike Doustdar as its new leader this week, 'but this won't be an easy fix,' warned Barclays' Field. Novo is due to report second-quarter results on Wednesday. One area that has been a particular headache for Novo is competition from cheaper copycat options for US patients. Compounding pharmacies are allowed to make and sell cheaper copies of a medicine when brand-name drugs are in short supply, and although they lost this permission this year, it remains an issue. Novo blamed its guidance cut on unrepentant compounders and broader competition. Many investors and analysts were caught off guard by the warning, with the mood in June being mainly one of optimism that a turnaround was starting. On Monday, nearly two-thirds of analysts tracked by Bloomberg rated the stock a buy or equivalent. But caution is starting to seep in, with less than half keeping their buy recommendations as of Friday's market close. Read: Novo Nordisk Shares Are Now Recovering from Peak Pessimism 'We got our call on Novo wrong,' said Rajesh Kumar, an analyst at HSBC. 'Our assumption that with FDA's ban on compounding, Novo might regain market share has not played out,' he wrote in a note on Thursday, cutting the stock to hold from buy. Still, one investor sees similarities between Novo's current situation and another upheaval for the drugmaker in 2016 when it was better known as the world's biggest maker of insulin. Will James, a fund manager at Guinness Global Investors, notes that back then, the company had its competitive position questioned. The guidance was cut and the CEO replaced. 'The share price fell and then recovered aggressively as Novo refocused its innovation and commercial efforts,' James said in an email. 'It is now undoubtedly a bigger job for the new CEO with a sizeable mountain to climb to regain and grow market share and rebuild trust with investors.' --With assistance from Michael Msika, Sagarika Jaisinghani and Blaise Robinson. More stories like this are available on
